Search for a trial

A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy

Primary objective of the study is•To investigate the change of Urinary Albumin-to-Creatinine ratio (UCAR) after 90 days treatment Secondary objectives of the study are•To assess safety and tolerability of these doses by assessing the effects on…

The impact of dietary nitrate supplementation on exercise-induced cardiac troponin T release in type 2 diabetic patients: a pilot-study

To assess whether dietary nitrate supplementation blunts the ischemia-reperfusion-induced rise in cTnT levels following exercise in type 2 diabetic patients.

A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality

The purpose of this study is to determine whether, in patients with type II diabetes at high risk for cardiovascular and/or renal events, aliskiren at a target dose of 300 mg o.d. compared to placebo, on top of conventional treatment, reduces…

A randomized clinical trial to study the effect of vitamin D supplementation on insulin sensitivity in Gestational Diabetes Mellitus

The main objective is to study the effect of vitamin D supplementation on insulin sensitivity in patients with gestational diabetes mellitus.

Safety and efficacy of TRC4186 in the treatment of stable heart failure associated with HbA1c >= 6.5 % or type 2 diabetes receiving oral hypoglycaemic therapy (with or without additional insulin) as an add-on to conventional treatment for heart failure

The objectives are to evaluate the safety and efficacy of TRC4186 and to define the recommended dose level for further pivotal studies.

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS

Primary:To evaluate the safety and tolerability profile of single escalating subcutaneous (sc) dose levels of HM11260C in adult patients with type 2 diabetes mellitusSecondary:To evaluate the dose response relationship of single escalating sc dose…

The effect of vildagliptin on endothelium-dependent vasodilatation. A double blind, cross-over study in type 2 diabetes mellitus.

Primary Objective: To determine whether a four week treatment with vildagliptin compared to acarbose improves endothelial dysfunction in patients with type 2 diabetes mellitus.Secondary Objective(s):-To determine the effect of vildagliptin on plasma…

A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase

OBJECTIVESPrimary ObjectiveThe primary objective is to evaluate the efficacy, safety, and tolerability of 800 and 1,200 mg/day of carisbamate compared with placebo in reducing the average daily pain in subjects with diabetic peripheral neuropathy (…

Effect of simvastatin on myocardial triglyceride accumulation, cardiac function and al vessel wall thickness in patients with type 2 diabetes mellitus

To study the possible beneficial effect of simvastatin on accumulation of triglycerides in the myocardium of patients with DM2 and the effect on vessel wall thickness using magnetic resonance imaging and spectroscopy

A Double-Blind clinical trial of Benfotiamine Treatment in Diabetic Nephropathy

-To investigate whether a short-term treatment (3 months) with benfotiamine in diabetic nephropathy patients leads to a reduction in urinary excretion of β2-microglobulin and albumin.-To investigate whether short-term treatment (3 months) with…

A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110

The primary objective of this study is to evaluate the effect of 12-week treatment with JNJ-16269110 on the glycated hemoglobin (HbA1c) concentration in subjects with T2DM.Additional objectives are to evaluate the effect of JNJ-16269110 on:1.…

A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia

Primary objective : Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients (no antidiabetic drug treatment in the last 6 months), with type 2 diabetes mellitus and dyslipidemia, to show that : - the efficacy of a…

Mechanisms of Albuminuria in Diabetes: Reversal of Injury to the Glycocalyx by the Ace-inhibitor Lisinopril

The primary objective of this study is to determine whether ACE inhibition results in an improvement of microvascular glycocalyx-thickness in patients with type 1 diabetes. The secondary objectives are to investigate whether this (hypothesized)…

A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS® Pioglitazone HCl in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Control on a Combination of Metformin and 30 mg of Pioglitazone HCl Therapy

The objective of the study is to evaluate the efficacy of the addition of SYR-322 (25 mg) to subjects who are inadequately controlled on pioglitazone HCl (30 mg) and metformin (*1500 mg or MTD).

The effect of rosiglitazone on ischemia-reperfusion-injury using annexin A5 scintigraphy.
A double blind placebo- controlled cross-over study in subjects with the metabolic syndrome

To estimate the effect of rosiglitazone compared to placebo on ischemia-reperfusion injury as assessed by annexin A5 scintigraphy in the human forearm in subjects with the metabolic syndrome.

Double-Blind follow-on study of Pitavastatine (4mg)versus atorvastatine (20 mg and 40 mg), with a single extension of treatment in patients with type II Diabetes Mellitus and Combined Dyslipidemia

To assess long-term safety and tolerability of pitavastatin 4 mg once daily (QD)To assess the efficacy of pitavastatin (4 mg QD) and simvastatin (40 mg and 80 mg QD) in terms of LDL-C target attainment (European Atherosclerosis Society [EAS] and…

Effects of SUlodexide on Postprandial lipidmetabolism in patiEnts with diabetes mellitus type II; Reversing dyslipidemia

To investigate whether treatment with sulodexide can reverse postprandial dyslipidemia in patients with type 2 diabetes mellitus

A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease.

Primary Objective:To evaluate the efficacy of ASP8232 in reducing Urinary Albumin Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to placebo.Secundary Objectives:1. To…

A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment
Randomized Withdrawal Study to Evaluate the Efficacy and Safety of
BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With
Confirmed Small Fibre Neuropathy That Is Idiopathic or Associated With
Diabetes Mellitus

The primary objective of this study is to evaluate the efficacy of BIIB074 in treating pain experienced by subjects with confirmed SFN that is idiopathic or associated with diabetes mellitus.Sub study objective:Corneal Confocal Microscopy (CCM) as a…

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

This study is designed to demonstrate the CV and renal effects of sotagliflozin in patients with T2D, high CV risk, and moderate renal impairment. One of the major objectives of this study is to fulfill the regulatory mandate that any new therapy…